ESMO 2019 | Kidney cancer: minimizing toxicities and hassle in adjuvant therapy

Tim Eisen

Tim Eisen, MBBChir, PhD, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses the issues seen with toxicity and the logistic of receiving adjuvant treatment in renal cell carcinoma within the setting of the SORCE trial (ISRCTN38934710) and touches on the proposed methods and aims of the RAMPART study (NCT03288532). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video